PACTG 1025

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 PACTG P1025是一项前瞻性队列研究，为收集和评估数据以及收集感染人类免疫缺陷病毒(HIV)的孕妇和产后妇女及其婴儿的资料库样本提供了一个框架。这项研究的主要目标是：评估为预防艾滋病毒垂直传播和/或为妇女健康开出的干预措施(例如，抗逆转录病毒疗法和分娩方式)的有效性；评估为妇女健康和/或预防艾滋病毒垂直传播开出的干预措施(例如，抗逆转录病毒疗法和分娩方式)的物质和婴儿安全性；为密集的分研究(如PACTG P1026，孕期药代动力学)、新工作概念表(NWCS)和数据分析概念表(DACS)提供框架和标本库，旨在进一步阐明艾滋病毒垂直传播的风险因素和机制，以及影响母婴结局的因素；评估感染艾滋病毒的孕妇在孕期和产后遵守抗逆转录病毒治疗的情况及其对妇女健康和垂直传播的影响，并评估婴儿对化学预防措施的遵守情况。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. PACTG P1025 is a prospective cohort study that provides a framework for collection and evaluation of data and collection of repository specimens from Human Immunodeficiency Virus (HIV)-infected pregnant and postpartum women and their infants. The primary objectives of this study are: to assess the effectiveness of interventions (e.g. antiretroviral therapy and mode of delivery) prescribed for prevention of vertical transmission of HIV and/or for women's health; to assess material and infant safety of interventions (e.g. Antiretroviral Therapy (ART) and mode of delivery) prescribed for women's health and/or for prevention of vertical transmission of HIV; to provide a framework and specimen repository for intensive substudies (such as PACTG P1026s, pharmacokinetics in pregnancy), New Works Concept Sheets (NWCS) and Data Analysis Concept Sheets (DACS) that aim to further elucidate risk factors for and mechanisms of vertical transmission of HIV, as well as factors that affect maternal and infant outcomes; to assess adherence to ART among HIV-infected pregnant women during pregnancy and postpartum and its impact on women's health and vertical transmission, and to assess adherence to chemoprophylaxsis in infants.